Thus, VEGF targeting was particularly effective at restricting primary tumor growth; in contrast, the Ang/Tie2 pathway-targeted agents (anti-Tie2, anti-Ang2, BowAng1) were relatively ineffective at controlling primary tumor growth (Fig. 1 and Supplemental Fig. S1). The gene discussed is TEK; the disease is neoplasm.